ICTI Software Used in Major Government Study
The New England Journal of Medicine published the results from a National Institute of Mental Health-funded study titled Clinical Antipsychotic Trial of Intervention Effectiveness – Schizophrenia (CATIE–SZ). ICTI is proud to reveal that the data for this study, conducted with 1493 subjects from 57 clinical sites in 24 states, was collected using an early version of ICTI’s iTrial EDC software.
Paris, France – The New England Journal of Medicine published the results from a National Institute of Mental Health-funded study titled Clinical Antipsychotic Trial of Intervention Effectiveness–Schizophrenia (CATIE–SZ). ICTI is proud to reveal that the data for this study, conducted with 1493 subjects from 57 clinical sites in 24 states, was collected using an early version of ICTI's iTrial EDC software.
The CATIE–SZ study looked at the effectiveness of five marketed antipsychotic drugs, allowing subjects to switch treatments during the study. iTrial EDC was used in combination with IVR (Interactive Voice Response) to gather real-time subject and treatment data for this study. The integration of data gathered over the phone with IVR as well as through the Internet with iTrial EDC allowed trial managers to access real time data and to review all study data in one place.
iTrial EDC's ability to work in any environment, whether or not an Internet connection is available, and its ease of integration with IVR resulted in its being chosen over another leading EDC technology for the CATIE–SZ study.
While iTrial EDC has continued to add enhancements since its launch seven years ago, it remains notable for its ability to work anywhere, to handle complexity in clinical trial design, and to easily integrate with other systems. Integration with ICTI's iVR system is now a standard offering to iTrial EDC's clients.
About ICTI and Almac Sciences
ICTI is a division of Almac Sciences that specializes in interactive solutions to accelerate the clinical trials process and reduce the costs of clinical trials. Our solutions include Interactive Voice Response (iVR) for patient randomization, dosing and clinical supply management; iDiary phone-based patient diaries; iTrial EDC for clinical trial data; and iForecasting for clinical trial materials planning.
Almac Sciences and its affiliated companies (CSS (Chemical Synthesis Services), CTS (Clinical Trial Services), ICTI (Interactive Clinical Technologies Incorporated), PDMS (Pharmaceutical Development and Manufacturing Services) and ArraDx (Array Based Diagnostics)) provide a broad range of services across drug discovery, diagnostics, pharmaceutical research and development, manufacture of API, clinical trials and drug product manufacture. US operations are based in Pennsylvania, North Carolina and California. European operations are headquartered in Craigavon, Northern Ireland with additional operations in London and Edinburgh.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Zerlasiran Achieves Significant Sustained Reduction in Lipoprotein(a) Levels with Infrequent Dosing
November 20th 2024Zerlasiran, a novel siRNA therapy, demonstrated over 80% sustained reductions in lipoprotein(a) levels with infrequent dosing in the Phase II ALPACAR-360 trial, highlighting its potential as a safe and effective treatment for patients at high risk of cardiovascular disease.
